Autoantibody against the amino acid sequence 661–680 in apo B-100 is associated with decreased carotid stenosis and cardiovascular events

Immunization with malondialdehyde (MDA)-modified peptides corresponding to the amino acid sequence between 661 and 680 in apo B-100 (p45) inhibits atherosclerosis in apo E knockout mice. The same effect can be obtained by treating the mice with recombinant anti-MDA-p45 IgG, suggesting that these ant...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Atherosclerosis Jg. 194; H. 2; S. e188 - e192
Hauptverfasser:	Fredrikson, Gunilla Nordin, Schiopu, Alexandru, Berglund, Göran, Alm, Ragnar, Shah, Prediman K., Nilsson, Jan
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Ireland Elsevier Ireland Ltd 01.10.2007
Schlagworte:	Aged Antibodies Apolipoprotein B-100 - genetics Apolipoprotein B-100 - immunology Apolipoproteins Autoantibodies - blood Autoantibodies - immunology Cardiology and Cardiovascular Disease Cardiovascular Carotid stenosis Case-Control Studies Clinical Medicine Cohort Studies Death, Sudden, Cardiac Female Humans Immunoglobulin G - blood Kardiologi och kardiovaskulära sjukdomar Klinisk medicin Male Medical and Health Sciences Medicin och hälsovetenskap Middle Aged Myocardial Infarction - immunology Peptide Peptide Fragments - immunology Peptides - immunology Risk Factors Ultrasound Carotid stenosis Antibodies Apolipoproteins Peptide Ultrasound
ISSN:	0021-9150, 1879-1484, 1879-1484
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	Immunization with malondialdehyde (MDA)-modified peptides corresponding to the amino acid sequence between 661 and 680 in apo B-100 (p45) inhibits atherosclerosis in apo E knockout mice. The same effect can be obtained by treating the mice with recombinant anti-MDA-p45 IgG, suggesting that these antibodies have atheroprotective effects. In the present study we analyzed if autoantibodies against p45 and MDA-p45 are related to carotid atherosclerosis and acute cardiovascular events in humans. Using a nested case control design we determined plasma levels of IgG recognizing native and MDA-modified p45 in baseline samples from 75 subjects with acute myocardial infarction or sudden cardiac death and 148 matched controls. The control group was found to have significantly higher levels of p45 IgG than the cases. Moreover, an independent association was found between high levels of MDA-p45 IgG and a low degree of carotid stenosis ( P = 0.006). There was a high degree of co-variation between IgG binding to native p45 and MDA-p45 ( r = 0.68, P < 0.0001). The associations between lower levels of autoantibodies against the apo B-100 p45 sequence and cardiovascular disease are in agreement with previous experimental studies demonstrating that these antibodies have atheroprotective effects. Our findings support the notion that the p45 sequence of apo B-100 is a potential target for immunomodulatory treatment of atherosclerosis in humans.
AbstractList	Immunization with malondialdehyde (MDA)-modified peptides corresponding to the amino acid sequence between 661 and 680 in apo B-100 (p45) inhibits atherosclerosis in apo E knockout mice. The same effect can be obtained by treating the mice with recombinant anti-MDA-p45 IgG, suggesting that these antibodies have atheroprotective effects. In the present study we analyzed if autoantibodies against p45 and MDA-p45 are related to carotid atherosclerosis and acute cardiovascular events in humans. Using a nested case control design we determined plasma levels of IgG recognizing native and MDA-modified p45 in baseline samples from 75 subjects with acute myocardial infarction or sudden cardiac death and 148 matched controls. The control group was found to have significantly higher levels of p45 IgG than the cases. Moreover, an independent association was found between high levels of MDA-p45 IgG and a low degree of carotid stenosis ( P = 0.006). There was a high degree of co-variation between IgG binding to native p45 and MDA-p45 ( r = 0.68, P < 0.0001). The associations between lower levels of autoantibodies against the apo B-100 p45 sequence and cardiovascular disease are in agreement with previous experimental studies demonstrating that these antibodies have atheroprotective effects. Our findings support the notion that the p45 sequence of apo B-100 is a potential target for immunomodulatory treatment of atherosclerosis in humans. Immunization with malondialdehyde (MDA)-modified peptides corresponding to the amino acid sequence between 661 and 680 in apo B-100 (p45) inhibits atherosclerosis in apo E knockout mice. The same effect can be obtained by treating the mice with recombinant anti-MDA-p45 IgG, suggesting that these antibodies have atheroprotective effects. In the present study we analyzed if autoantibodies against p45 and MDA-p45 are related to carotid atherosclerosis and acute cardiovascular events in humans. Using a nested case control design we determined plasma levels of IgG recognizing native and MDA-modified p45 in baseline samples from 75 subjects with acute myocardial infarction or sudden cardiac death and 148 matched controls. The control group was found to have significantly higher levels of p45 IgG than the cases. Moreover, an independent association was found between high levels of MDA-p45 IgG and a low degree of carotid stenosis (P=0.006). There was a high degree of co-variation between IgG binding to native p45 and MDA-p45 (r=0.68, P<0.0001). The associations between lower levels of autoantibodies against the apo B-100 p45 sequence and cardiovascular disease are in agreement with previous experimental studies demonstrating that these antibodies have atheroprotective effects. Our findings support the notion that the p45 sequence of apo B-100 is a potential target for immunomodulatory treatment of atherosclerosis in humans. Abstract Immunization with malondialdehyde (MDA)-modified peptides corresponding to the amino acid sequence between 661 and 680 in apo B-100 (p45) inhibits atherosclerosis in apo E knockout mice. The same effect can be obtained by treating the mice with recombinant anti-MDA-p45 IgG, suggesting that these antibodies have atheroprotective effects. In the present study we analyzed if autoantibodies against p45 and MDA-p45 are related to carotid atherosclerosis and acute cardiovascular events in humans. Using a nested case control design we determined plasma levels of IgG recognizing native and MDA-modified p45 in baseline samples from 75 subjects with acute myocardial infarction or sudden cardiac death and 148 matched controls. The control group was found to have significantly higher levels of p45 IgG than the cases. Moreover, an independent association was found between high levels of MDA-p45 IgG and a low degree of carotid stenosis ( P = 0.006). There was a high degree of co-variation between IgG binding to native p45 and MDA-p45 ( r = 0.68, P < 0.0001). The associations between lower levels of autoantibodies against the apo B-100 p45 sequence and cardiovascular disease are in agreement with previous experimental studies demonstrating that these antibodies have atheroprotective effects. Our findings support the notion that the p45 sequence of apo B-100 is a potential target for immunomodulatory treatment of atherosclerosis in humans. Immunization with malondialdehyde (MDA)-modified peptides corresponding to the amino acid sequence between 661 and 680 in apo B-100 (p45) inhibits atherosclerosis in apo E knockout mice. The same effect can be obtained by treating the mice with recombinant anti-MDA-p45 IgG, suggesting that these antibodies have atheroprotective effects. In the present study we analyzed if autoantibodies against p45 and MDA-p45 are related to carotid atherosclerosis and acute cardiovascular events in humans. Using a nested case control design we determined plasma levels of IgG recognizing native and MDA-modified p45 in baseline samples from 75 subjects with acute myocardial infarction or sudden cardiac death and 148 matched controls. The control group was found to have significantly higher levels of p45 IgG than the cases. Moreover, an independent association was found between high levels of MDA-p45 IgG and a low degree of carotid stenosis (P=0.006). There was a high degree of co-variation between IgG binding to native p45 and MDA-p45 (r=0.68, P<0.0001). The associations between lower levels of autoantibodies against the apo B-100 p45 sequence and cardiovascular disease are in agreement with previous experimental studies demonstrating that these antibodies have atheroprotective effects. Our findings support the notion that the p45 sequence of apo B-100 is a potential target for immunomodulatory treatment of atherosclerosis in humans.Immunization with malondialdehyde (MDA)-modified peptides corresponding to the amino acid sequence between 661 and 680 in apo B-100 (p45) inhibits atherosclerosis in apo E knockout mice. The same effect can be obtained by treating the mice with recombinant anti-MDA-p45 IgG, suggesting that these antibodies have atheroprotective effects. In the present study we analyzed if autoantibodies against p45 and MDA-p45 are related to carotid atherosclerosis and acute cardiovascular events in humans. Using a nested case control design we determined plasma levels of IgG recognizing native and MDA-modified p45 in baseline samples from 75 subjects with acute myocardial infarction or sudden cardiac death and 148 matched controls. The control group was found to have significantly higher levels of p45 IgG than the cases. Moreover, an independent association was found between high levels of MDA-p45 IgG and a low degree of carotid stenosis (P=0.006). There was a high degree of co-variation between IgG binding to native p45 and MDA-p45 (r=0.68, P<0.0001). The associations between lower levels of autoantibodies against the apo B-100 p45 sequence and cardiovascular disease are in agreement with previous experimental studies demonstrating that these antibodies have atheroprotective effects. Our findings support the notion that the p45 sequence of apo B-100 is a potential target for immunomodulatory treatment of atherosclerosis in humans.
Author	Berglund, Göran Schiopu, Alexandru Nilsson, Jan Fredrikson, Gunilla Nordin Shah, Prediman K. Alm, Ragnar
Author_xml	– sequence: 1 givenname: Gunilla Nordin surname: Fredrikson fullname: Fredrikson, Gunilla Nordin organization: Department of Clinical Sciences, Malmö University Hospital, Lund University, Sweden – sequence: 2 givenname: Alexandru surname: Schiopu fullname: Schiopu, Alexandru organization: Department of Clinical Sciences, Malmö University Hospital, Lund University, Sweden – sequence: 3 givenname: Göran surname: Berglund fullname: Berglund, Göran organization: Department of Clinical Sciences, Malmö University Hospital, Lund University, Sweden – sequence: 4 givenname: Ragnar surname: Alm fullname: Alm, Ragnar organization: Department of Clinical Sciences, Malmö University Hospital, Lund University, Sweden – sequence: 5 givenname: Prediman K. surname: Shah fullname: Shah, Prediman K. organization: Atherosclerosis Research Center, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, USA – sequence: 6 givenname: Jan surname: Nilsson fullname: Nilsson, Jan email: jan.nilsson@med.lu.se organization: Department of Clinical Sciences, Malmö University Hospital, Lund University, Sweden
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/17214995$$D View this record in MEDLINE/PubMed
BookMark	eNqVUk1v1DAQjVAR_YC_gHyB2y527DjJAaRSlYJUiQNwHs3aE-olay-206o37hz5h_wSnG7poRJSudga6817zzPvsNrzwVNVvRB8KbjQr9ZLzBcUQzLjfLq0rDnXS1EvuVCPqgPRtf1CqE7tVQec12LRi4bvV4cprTnnqhXdk2pftLVQfd8cVD-PpxzQZ7cK9prhV3Q-ZVYUGG6cDwyNsyzR94m8Iaa1-P3jl-44c57hNrC3C8FLkRimFIzDTJZduXzBLJlImEppMIY8k2Tys1-G_ubRunCJyUwjRkaX5HN6Wj0ecEz07PY-qr68O_188n5x_vHsw8nx-cJo1eeFlBZbso1pZEPlEy3yoVaCpBTdoM0g7YA4IK2Uok63dmWstlyZTqLUapDyqMIdb7qi7bSCbXQbjNcQ0ME2xIwjREqE0VzAOEEiKKjRGcwu-AS8tdS2PQEpW4PSDUHf8lLKWuiukUTUF42XO41tDGV4KcPGJUPjiJ7ClEB3sml6zQvw-S1wWm3I3pn5u6ICONkBTFl3ijSAcfnGSo7oRhAc5mDAGu4FA-ZggKihBKOwvL7Hcif0wP6zXT-VxVw6ipCMmzNhXSSTwQb3YKY395jM6HyZ7viNrimtwxR92T4ISKUBPs0hnjPMNedt04lCcPpvgv8w8ge1mxG-
CitedBy_id	crossref_primary_10_1007_s00125_009_1377_9 crossref_primary_10_1016_j_atherosclerosis_2015_01_023 crossref_primary_10_1097_MOL_0b013e328356ec7c crossref_primary_10_1134_S1990750816040028 crossref_primary_10_3390_ph14040330 crossref_primary_10_1111_joim_12659 crossref_primary_10_1093_cvr_cvx112 crossref_primary_10_1093_cvr_cvab285 crossref_primary_10_1371_journal_pone_0120744 crossref_primary_10_1111_j_1365_2796_2008_01945_x crossref_primary_10_1111_joim_12357 crossref_primary_10_1038_s44161_023_00376_x crossref_primary_10_4049_jimmunol_0902654 crossref_primary_10_1016_j_cca_2012_04_031 crossref_primary_10_1074_jbc_RA117_000292 crossref_primary_10_1093_eurheartj_ehn336 crossref_primary_10_1111_joim_12353 crossref_primary_10_1016_j_atherosclerosis_2010_06_007 crossref_primary_10_1111_j_1365_2796_2008_01995_x crossref_primary_10_1016_j_tcm_2010_02_010 crossref_primary_10_1161_ATVBAHA_124_319843 crossref_primary_10_1042_BSR20180450 crossref_primary_10_1080_14760584_2017_1258309 crossref_primary_10_17816_MAJ16329_34 crossref_primary_10_1161_ATVBAHA_115_306938 crossref_primary_10_1084_jem_20092243 crossref_primary_10_1016_j_atherosclerosis_2012_07_021 crossref_primary_10_1016_j_atherosclerosis_2012_10_074 crossref_primary_10_3109_08916934_2014_1003641 crossref_primary_10_2174_0109298673348217241119063941 crossref_primary_10_1371_journal_pone_0058364 crossref_primary_10_1111_j_1365_2796_2009_02150_x crossref_primary_10_1111_cei_12651 crossref_primary_10_1016_j_vaccine_2019_12_039 crossref_primary_10_1136_heartasia_2018_011018 crossref_primary_10_1016_j_imbio_2010_11_003 crossref_primary_10_1016_j_atherosclerosis_2013_11_041 crossref_primary_10_1016_j_atherosclerosis_2008_11_020 crossref_primary_10_1186_1471_230X_10_48 crossref_primary_10_1586_erv_13_4 crossref_primary_10_1016_j_jacc_2007_07_081 crossref_primary_10_1016_j_jacc_2009_02_041 crossref_primary_10_1016_j_fob_2015_08_006 crossref_primary_10_1155_2012_571846 crossref_primary_10_1016_j_atherosclerosis_2018_01_022 crossref_primary_10_1016_j_atherosclerosis_2008_05_025 crossref_primary_10_1111_j_1365_2796_2008_02067_x crossref_primary_10_1016_j_atherosclerosis_2010_07_014
Cites_doi	10.1161/01.ATV.16.8.1074 10.1172/JCI7272 10.1056/NEJMra043430 10.1161/01.ATV.0000067937.93716.DB 10.1161/01.ATV.18.12.1972 10.1172/JCI119892 10.1016/S0735-1097(97)00366-5 10.1172/JCI8472 10.1161/01.CIR.0000143162.56057.B5 10.1161/01.ATV.10.3.325 10.1056/NEJMoa043175 10.1073/pnas.92.9.3893 10.1161/01.ATV.0000012455.62765.BF 10.1016/S0021-9150(98)00015-X 10.1161/01.ATV.21.1.108 10.1161/01.CIR.103.13.1721 10.1161/01.ATV.0000067935.02679.B0 10.1016/j.bbrc.2005.10.141 10.1161/01.RES.0000029784.15893.10 10.1073/pnas.92.3.821 10.1161/01.ATV.0000039169.47943.EE 10.1016/j.atherosclerosis.2004.04.016 10.1073/pnas.86.4.1372 10.1038/nm1102-1218 10.1080/08916930500050525
ContentType	Journal Article
Copyright	2007 Elsevier Ireland Ltd Elsevier Ireland Ltd
Copyright_xml	– notice: 2007 Elsevier Ireland Ltd – notice: Elsevier Ireland Ltd
CorporateAuthor	Faculty of Medicine Internmedicin - epidemiologi Lunds universitet Department of Clinical Sciences, Malmö Medicinska fakulteten Lund University Kardiovaskulär forskning - immunitet och ateroskleros Cardiovascular Research - Immunity and Atherosclerosis Institutionen för kliniska vetenskaper, Malmö Internal Medicine - Epidemiology
CorporateAuthor_xml	– name: Faculty of Medicine – name: Medicinska fakulteten – name: Lund University – name: Cardiovascular Research - Immunity and Atherosclerosis – name: Kardiovaskulär forskning - immunitet och ateroskleros – name: Internmedicin - epidemiologi – name: Institutionen för kliniska vetenskaper, Malmö – name: Internal Medicine - Epidemiology – name: Lunds universitet – name: Department of Clinical Sciences, Malmö
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 ADTPV AGCHP AOWAS D8T D95 ZZAVC
DOI	10.1016/j.atherosclerosis.2006.12.014
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic SwePub SWEPUB Lunds universitet full text SwePub Articles SWEPUB Freely available online SWEPUB Lunds universitet SwePub Articles full text
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1879-1484
EndPage	e192
ExternalDocumentID	oai_portal_research_lu_se_publications_07de779e_e4d2_465e_970e_e3216853eee9 17214995 10_1016_j_atherosclerosis_2006_12_014 S0021915006007581 1_s2_0_S0021915006007581
Genre	Research Support, Non-U.S. Gov't Journal Article
GroupedDBID	--- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 23N 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAFWJ AAIKJ AAKOC AALRI AAOAW AAQFI AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABJNI ABLJU ABMAC ABMZM ABOCM ABXDB ACDAQ ACGFS ACIEU ACIUM ACLOT ACRLP ACVFH ADBBV ADCNI ADEZE AEBSH AEIPS AEKER AENEX AEUPX AEVXI AEXQZ AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEB HMK HMO HVGLF HZ~ IHE J1W J5H K-O KOM L7B M27 M41 MO0 N9A O-L O9- OAUVE OA~ OK1 OL0 OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K WUQ X7M Z5R ZGI ZXP ~G- ~HD ~KM AACTN AFCTW AFKWA AJOXV AMFUW NCXOZ RIG 0SF AAIAV ABLVK ABYKQ AHPSJ AJBFU LCYCR ZA5 9DU AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 ADTPV AGCHP AOWAS D8T D95 ZZAVC
ID	FETCH-LOGICAL-c649t-33da7ed5c535e9957a0f241e3318f6cf3dfaafaeb44e867dbcd6d04c83a364f33
ISICitedReferencesCount	54
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000208579100025&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0021-9150 1879-1484
IngestDate	Wed Oct 15 12:40:20 EDT 2025 Wed Oct 01 14:44:03 EDT 2025 Wed Feb 19 01:46:55 EST 2025 Sat Nov 29 06:30:50 EST 2025 Tue Nov 18 21:50:45 EST 2025 Fri Feb 23 02:28:04 EST 2024 Sun Feb 23 10:19:13 EST 2025 Tue Oct 14 19:32:43 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	2
Keywords	Carotid stenosis Antibodies Apolipoproteins Peptide Ultrasound
Language	English
License	https://www.elsevier.com/tdm/userlicense/1.0
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-c649t-33da7ed5c535e9957a0f241e3318f6cf3dfaafaeb44e867dbcd6d04c83a364f33
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://lup.lub.lu.se/record/164998
PMID	17214995
PQID	68355960
PQPubID	23479
ParticipantIDs	swepub_primary_oai_portal_research_lu_se_publications_07de779e_e4d2_465e_970e_e3216853eee9 proquest_miscellaneous_68355960 pubmed_primary_17214995 crossref_citationtrail_10_1016_j_atherosclerosis_2006_12_014 crossref_primary_10_1016_j_atherosclerosis_2006_12_014 elsevier_sciencedirect_doi_10_1016_j_atherosclerosis_2006_12_014 elsevier_clinicalkeyesjournals_1_s2_0_S0021915006007581 elsevier_clinicalkey_doi_10_1016_j_atherosclerosis_2006_12_014
PublicationCentury	2000
PublicationDate	2007-10-01
PublicationDateYYYYMMDD	2007-10-01
PublicationDate_xml	– month: 10 year: 2007 text: 2007-10-01 day: 01
PublicationDecade	2000
PublicationPlace	Ireland
PublicationPlace_xml	– name: Ireland
PublicationTitle	Atherosclerosis
PublicationTitleAlternate	Atherosclerosis
PublicationYear	2007
Publisher	Elsevier Ireland Ltd
Publisher_xml	– name: Elsevier Ireland Ltd
References	Binder, Chang, Shaw (bib1) 2002; 8 Stemme, Faber, Holm (bib3) 1995; 92 Caligiuri, Nicoletti, Poirier, Hansson (bib21) 2002; 109 Nicoletti, Kaveri, Caligiuri, Bariety, Hansson (bib23) 1998; 102 Palinski, Miller, Witztum (bib6) 1995; 92 Fredrikson, Hedblad, Berglund (bib13) 2003; 23 Fredrikson, Andersson, Soderberg (bib15) 2005; 38 Chyu, Reyes, Zhao (bib5) 2004; 176 Hansson (bib24) 2005; 352 George, Afek, Gilburd (bib10) 1998; 138 Nilsson, Calara, Regnstrom (bib8) 1997; 30 Schiopu, Bengtsson, Soderberg (bib17) 2004; 110 Zhou, Caligiuri, Hamsten, Lefvert, Hansson (bib11) 2001; 21 Palinski, Rosenfeld, Yla-Herttuala (bib4) 1989; 86 Tsimikas, Brilakis, Miller (bib25) 2005; 353 Shaw, Horkko, Chang (bib12) 2000; 105 Dimayuga, Cercek, Oguchi (bib22) 2002; 22 Hansson, Libby, Schonbeck, Yan (bib2) 2002; 91 Palinski, Yla-Herttuala, Rosenfeld (bib19) 1990; 10 Chyu, Zhao, Reyes (bib16) 2005; 338 Ameli, Hultgardh-Nilsson, Regnstrom (bib7) 1996; 16 Freigang, Horkko, Miller, Witztum, Palinski (bib9) 1998; 18 Fredrikson, Soderberg, Lindholm (bib14) 2003; 23 Major, Fazio, Linton (bib20) 2002; 22 Hedblad, Wikstrand, Janzon, Wedel, Berglund (bib18) 2001; 103 Nilsson (10.1016/j.atherosclerosis.2006.12.014_bib8) 1997; 30 Zhou (10.1016/j.atherosclerosis.2006.12.014_bib11) 2001; 21 Chyu (10.1016/j.atherosclerosis.2006.12.014_bib16) 2005; 338 Schiopu (10.1016/j.atherosclerosis.2006.12.014_bib17) 2004; 110 Ameli (10.1016/j.atherosclerosis.2006.12.014_bib7) 1996; 16 Caligiuri (10.1016/j.atherosclerosis.2006.12.014_bib21) 2002; 109 Tsimikas (10.1016/j.atherosclerosis.2006.12.014_bib25) 2005; 353 Major (10.1016/j.atherosclerosis.2006.12.014_bib20) 2002; 22 Fredrikson (10.1016/j.atherosclerosis.2006.12.014_bib15) 2005; 38 Hansson (10.1016/j.atherosclerosis.2006.12.014_bib2) 2002; 91 Shaw (10.1016/j.atherosclerosis.2006.12.014_bib12) 2000; 105 Stemme (10.1016/j.atherosclerosis.2006.12.014_bib3) 1995; 92 Palinski (10.1016/j.atherosclerosis.2006.12.014_bib19) 1990; 10 Freigang (10.1016/j.atherosclerosis.2006.12.014_bib9) 1998; 18 Palinski (10.1016/j.atherosclerosis.2006.12.014_bib4) 1989; 86 Hansson (10.1016/j.atherosclerosis.2006.12.014_bib24) 2005; 352 Nicoletti (10.1016/j.atherosclerosis.2006.12.014_bib23) 1998; 102 Fredrikson (10.1016/j.atherosclerosis.2006.12.014_bib13) 2003; 23 George (10.1016/j.atherosclerosis.2006.12.014_bib10) 1998; 138 Dimayuga (10.1016/j.atherosclerosis.2006.12.014_bib22) 2002; 22 Palinski (10.1016/j.atherosclerosis.2006.12.014_bib6) 1995; 92 Chyu (10.1016/j.atherosclerosis.2006.12.014_bib5) 2004; 176 Binder (10.1016/j.atherosclerosis.2006.12.014_bib1) 2002; 8 Fredrikson (10.1016/j.atherosclerosis.2006.12.014_bib14) 2003; 23 Hedblad (10.1016/j.atherosclerosis.2006.12.014_bib18) 2001; 103
References_xml	– volume: 353 start-page: 46 year: 2005 end-page: 57 ident: bib25 article-title: Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease publication-title: N Engl J Med – volume: 16 start-page: 1074 year: 1996 end-page: 1079 ident: bib7 article-title: Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits publication-title: Arterioscler Thromb Vasc Biol – volume: 21 start-page: 108 year: 2001 end-page: 114 ident: bib11 article-title: LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis publication-title: Arterioscler Thromb Vasc Biol – volume: 23 start-page: 872 year: 2003 end-page: 878 ident: bib13 article-title: Identification of immune responses against aldehyde-modified peptide sequences in apo B-100 associated with cardiovascular disease publication-title: Arterioscler Thromb Vasc Biol – volume: 92 start-page: 3893 year: 1995 end-page: 3897 ident: bib3 article-title: T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein publication-title: Proc Natl Acad Sci USA – volume: 176 start-page: 27 year: 2004 end-page: 35 ident: bib5 article-title: Timing affects the efficacy of LDL immunization on atherosclerotic lesions in apo E (−/−) mice publication-title: Atherosclerosis – volume: 352 start-page: 1685 year: 2005 end-page: 1695 ident: bib24 article-title: Inflammation, atherosclerosis, and coronary artery disease publication-title: N Engl J Med – volume: 23 start-page: 879 year: 2003 end-page: 884 ident: bib14 article-title: Inhibition of atherosclerosis in ApoE-null mice by immunization with ApoB-100 peptide sequences publication-title: Arterioscler Thromb Vasc Biol – volume: 86 start-page: 1372 year: 1989 end-page: 1376 ident: bib4 article-title: Low density lipoprotein undergoes oxidative modification in vivo publication-title: Proc Natl Acad Sci USA – volume: 30 start-page: 1886 year: 1997 end-page: 1891 ident: bib8 article-title: Immunization with homologous oxidized low density lipoprotein reduces neointimal formation after balloon injury in hypercholesterolemic rabbits publication-title: J Am Coll Cardiol – volume: 105 start-page: 1731 year: 2000 end-page: 1740 ident: bib12 article-title: Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity publication-title: J Clin Invest – volume: 109 start-page: 745 year: 2002 end-page: 753 ident: bib21 article-title: Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice publication-title: J Clin Invest – volume: 102 start-page: 910 year: 1998 end-page: 918 ident: bib23 article-title: Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice publication-title: J Clin Invest – volume: 22 start-page: 644 year: 2002 end-page: 649 ident: bib22 article-title: Inhibitory effect on arterial injury-induced neointimal formation by adoptive B-cell transfer in Rag-1 knockout mice publication-title: Arterioscler Thromb Vasc Biol – volume: 91 start-page: 281 year: 2002 end-page: 291 ident: bib2 article-title: Innate and adaptive immunity in the pathogenesis of atherosclerosis publication-title: Circ Res – volume: 110 start-page: 2047 year: 2004 end-page: 2052 ident: bib17 article-title: Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis publication-title: Circulation – volume: 10 start-page: 325 year: 1990 end-page: 335 ident: bib19 article-title: Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein publication-title: Arteriosclerosis – volume: 18 start-page: 1972 year: 1998 end-page: 1982 ident: bib9 article-title: Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes publication-title: Arterioscler Thromb Vasc Biol – volume: 92 start-page: 821 year: 1995 end-page: 825 ident: bib6 article-title: Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis publication-title: Proc Natl Acad Sci USA – volume: 338 start-page: 1982 year: 2005 end-page: 1989 ident: bib16 article-title: Immunization using an Apo B-100 related epitope reduces atherosclerosis and plaque inflammation in hypercholesterolemic apo E (−/−) mice publication-title: Biochem Biophys Res Commun – volume: 38 start-page: 171 year: 2005 end-page: 179 ident: bib15 article-title: Atheroprotective immunization with MDA-modified apo B-100 peptide sequences is associated with activation of Th2 specific antibody expression publication-title: Autoimmunity – volume: 103 start-page: 1721 year: 2001 end-page: 1726 ident: bib18 article-title: Low dose metropolol CR/XL and fluvastatin slow progression of carotid intima-media thickness (IMT). Main results from the beta-blocker cholesterol asymptomatic plaque study (BCAPS) publication-title: Circulation – volume: 138 start-page: 147 year: 1998 end-page: 152 ident: bib10 article-title: Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis publication-title: Atherosclerosis – volume: 8 start-page: 1218 year: 2002 end-page: 1226 ident: bib1 article-title: Innate and acquired immunity in atherogenesis publication-title: Nat Med – volume: 22 start-page: 1892 year: 2002 end-page: 1898 ident: bib20 article-title: B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice publication-title: Arterioscler Thromb Vasc Biol – volume: 16 start-page: 1074 year: 1996 ident: 10.1016/j.atherosclerosis.2006.12.014_bib7 article-title: Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/01.ATV.16.8.1074 – volume: 109 start-page: 745 year: 2002 ident: 10.1016/j.atherosclerosis.2006.12.014_bib21 article-title: Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice publication-title: J Clin Invest doi: 10.1172/JCI7272 – volume: 352 start-page: 1685 year: 2005 ident: 10.1016/j.atherosclerosis.2006.12.014_bib24 article-title: Inflammation, atherosclerosis, and coronary artery disease publication-title: N Engl J Med doi: 10.1056/NEJMra043430 – volume: 23 start-page: 879 year: 2003 ident: 10.1016/j.atherosclerosis.2006.12.014_bib14 article-title: Inhibition of atherosclerosis in ApoE-null mice by immunization with ApoB-100 peptide sequences publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/01.ATV.0000067937.93716.DB – volume: 18 start-page: 1972 year: 1998 ident: 10.1016/j.atherosclerosis.2006.12.014_bib9 article-title: Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/01.ATV.18.12.1972 – volume: 102 start-page: 910 year: 1998 ident: 10.1016/j.atherosclerosis.2006.12.014_bib23 article-title: Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice publication-title: J Clin Invest doi: 10.1172/JCI119892 – volume: 30 start-page: 1886 year: 1997 ident: 10.1016/j.atherosclerosis.2006.12.014_bib8 article-title: Immunization with homologous oxidized low density lipoprotein reduces neointimal formation after balloon injury in hypercholesterolemic rabbits publication-title: J Am Coll Cardiol doi: 10.1016/S0735-1097(97)00366-5 – volume: 105 start-page: 1731 year: 2000 ident: 10.1016/j.atherosclerosis.2006.12.014_bib12 article-title: Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity publication-title: J Clin Invest doi: 10.1172/JCI8472 – volume: 110 start-page: 2047 year: 2004 ident: 10.1016/j.atherosclerosis.2006.12.014_bib17 article-title: Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis publication-title: Circulation doi: 10.1161/01.CIR.0000143162.56057.B5 – volume: 10 start-page: 325 year: 1990 ident: 10.1016/j.atherosclerosis.2006.12.014_bib19 article-title: Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein publication-title: Arteriosclerosis doi: 10.1161/01.ATV.10.3.325 – volume: 353 start-page: 46 year: 2005 ident: 10.1016/j.atherosclerosis.2006.12.014_bib25 article-title: Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease publication-title: N Engl J Med doi: 10.1056/NEJMoa043175 – volume: 92 start-page: 3893 year: 1995 ident: 10.1016/j.atherosclerosis.2006.12.014_bib3 article-title: T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.92.9.3893 – volume: 22 start-page: 644 year: 2002 ident: 10.1016/j.atherosclerosis.2006.12.014_bib22 article-title: Inhibitory effect on arterial injury-induced neointimal formation by adoptive B-cell transfer in Rag-1 knockout mice publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/01.ATV.0000012455.62765.BF – volume: 138 start-page: 147 year: 1998 ident: 10.1016/j.atherosclerosis.2006.12.014_bib10 article-title: Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis publication-title: Atherosclerosis doi: 10.1016/S0021-9150(98)00015-X – volume: 21 start-page: 108 year: 2001 ident: 10.1016/j.atherosclerosis.2006.12.014_bib11 article-title: LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/01.ATV.21.1.108 – volume: 103 start-page: 1721 year: 2001 ident: 10.1016/j.atherosclerosis.2006.12.014_bib18 article-title: Low dose metropolol CR/XL and fluvastatin slow progression of carotid intima-media thickness (IMT). Main results from the beta-blocker cholesterol asymptomatic plaque study (BCAPS) publication-title: Circulation doi: 10.1161/01.CIR.103.13.1721 – volume: 23 start-page: 872 year: 2003 ident: 10.1016/j.atherosclerosis.2006.12.014_bib13 article-title: Identification of immune responses against aldehyde-modified peptide sequences in apo B-100 associated with cardiovascular disease publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/01.ATV.0000067935.02679.B0 – volume: 338 start-page: 1982 year: 2005 ident: 10.1016/j.atherosclerosis.2006.12.014_bib16 article-title: Immunization using an Apo B-100 related epitope reduces atherosclerosis and plaque inflammation in hypercholesterolemic apo E (−/−) mice publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2005.10.141 – volume: 91 start-page: 281 year: 2002 ident: 10.1016/j.atherosclerosis.2006.12.014_bib2 article-title: Innate and adaptive immunity in the pathogenesis of atherosclerosis publication-title: Circ Res doi: 10.1161/01.RES.0000029784.15893.10 – volume: 92 start-page: 821 year: 1995 ident: 10.1016/j.atherosclerosis.2006.12.014_bib6 article-title: Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.92.3.821 – volume: 22 start-page: 1892 year: 2002 ident: 10.1016/j.atherosclerosis.2006.12.014_bib20 article-title: B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/01.ATV.0000039169.47943.EE – volume: 176 start-page: 27 year: 2004 ident: 10.1016/j.atherosclerosis.2006.12.014_bib5 article-title: Timing affects the efficacy of LDL immunization on atherosclerotic lesions in apo E (−/−) mice publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2004.04.016 – volume: 86 start-page: 1372 year: 1989 ident: 10.1016/j.atherosclerosis.2006.12.014_bib4 article-title: Low density lipoprotein undergoes oxidative modification in vivo publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.86.4.1372 – volume: 8 start-page: 1218 year: 2002 ident: 10.1016/j.atherosclerosis.2006.12.014_bib1 article-title: Innate and acquired immunity in atherogenesis publication-title: Nat Med doi: 10.1038/nm1102-1218 – volume: 38 start-page: 171 year: 2005 ident: 10.1016/j.atherosclerosis.2006.12.014_bib15 article-title: Atheroprotective immunization with MDA-modified apo B-100 peptide sequences is associated with activation of Th2 specific antibody expression publication-title: Autoimmunity doi: 10.1080/08916930500050525
SSID	ssj0004718
Score	2.1199098
Snippet	Immunization with malondialdehyde (MDA)-modified peptides corresponding to the amino acid sequence between 661 and 680 in apo B-100 (p45) inhibits... Abstract Immunization with malondialdehyde (MDA)-modified peptides corresponding to the amino acid sequence between 661 and 680 in apo B-100 (p45) inhibits...
SourceID	swepub proquest pubmed crossref elsevier
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	e188
SubjectTerms	Aged Antibodies Apolipoprotein B-100 - genetics Apolipoprotein B-100 - immunology Apolipoproteins Autoantibodies - blood Autoantibodies - immunology Cardiology and Cardiovascular Disease Cardiovascular Carotid stenosis Case-Control Studies Clinical Medicine Cohort Studies Death, Sudden, Cardiac Female Humans Immunoglobulin G - blood Kardiologi och kardiovaskulära sjukdomar Klinisk medicin Male Medical and Health Sciences Medicin och hälsovetenskap Middle Aged Myocardial Infarction - immunology Peptide Peptide Fragments - immunology Peptides - immunology Risk Factors Ultrasound
Title	Autoantibody against the amino acid sequence 661–680 in apo B-100 is associated with decreased carotid stenosis and cardiovascular events
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S0021915006007581 https://www.clinicalkey.es/playcontent/1-s2.0-S0021915006007581 https://dx.doi.org/10.1016/j.atherosclerosis.2006.12.014 https://www.ncbi.nlm.nih.gov/pubmed/17214995 https://www.proquest.com/docview/68355960
Volume	194
WOSCitedRecordID	wos000208579100025&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1879-1484 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0004718 issn: 0021-9150 databaseCode: AIEXJ dateStart: 19950106 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtZ3Nb9MwFMCtsaGJC-JzlI_hA5yqoiRO4lhCiA6NARITgiFVXCwndrZMJamSZho37hz5DznyV_AcO0m7AeqQuERtWrtJ3q_28_P7QOiRdDyZMOWPYsroCAY8dxSTmI2CNIojX0QJIaIpNkH396PJhL1bW_vZxsKcTGmeR6enbPZfRQ3nQNg6dPYC4u46hRPwGoQORxA7HFcS_LieF_C4sriQX4biEFb-VROvOBSfs7wYiiSTw9aBegjzZuvuQMLI0dYPMSuGOzBuOrrWubDSa53UZaNlVvBW1_uZ667mOt14ZlI9J8verU12qGpR_x1rfbOo4JJL3aijp1SyzNpg_70617WQ9J6SzDp4PyRHWTGrF6JyyrozJqjycFobG_me3vvfCcse-7Gx-74Xh7kol8wctHOY68MOXBiZTZbabug2BZIto97CQKxcUy3QTurKNRX3zk0YxnZx_EQs377ZpdJ2YhPiupyo-8wE2rk1th5zx_xMd7rYZ8hdjzu65vqGRwMWraON8evdyZs-ipe6Rm-wN7qJHvfeiH-5vj9pVOdXTGfS4TYq1ME1dNWuffDYMHsdran8Btp8a707bqJvi-hiiy6GS8INuliji1t0MaD74-t3gBZnOQZocQMtzircQ4s1tLiDFltocQstBorwMrTYQHsLfXy5e_Di1cgWCxkloc_mI0KkoEoGSUACxVhAhZOCdqoITFppmKREpkKkQsW-r6KQyjiRoXT8JCKChH5KyG20nhe5uoMw8xwqaKKSKEhhda7iVMXSBW0yYsINYneAnrYPnCc2k74u6DLlKwEwQGHXfGZSyqza8FkrXd7GTcNMz4HlVTugv-tAVXb4qrjLK_gm1y4crmbQ0eUrgghu-XnX0qrmRuW-yI8_bIHkMIXpfUmRq6KueAirwICFzgBtGU77x0I91wdhDtAnA273ic6KbwwU3GZFO-LTmleKzxa2O7hDpaKUKa586XE_DBRn1IG3xHNDWKkopdjdf5XHPXSlH6nuo_V5WasH6HJyMs-qchtdopNo2_7JfwEa4k0t
linkProvider	Elsevier
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Autoantibody+against+the+amino+acid+sequence+661%E2%80%93680+in+apo+B-100+is+associated+with+decreased+carotid+stenosis+and+cardiovascular+events&rft.jtitle=Atherosclerosis&rft.au=Fredrikson%2C+Gunilla+Nordin&rft.au=Schiopu%2C+Alexandru&rft.au=Berglund%2C+G%C3%B6ran&rft.au=Alm%2C+Ragnar&rft.date=2007-10-01&rft.issn=0021-9150&rft.volume=194&rft.issue=2&rft.spage=e188&rft.epage=e192&rft_id=info:doi/10.1016%2Fj.atherosclerosis.2006.12.014&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_atherosclerosis_2006_12_014
thumbnail_m	http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00219150%2FS0021915007X04489%2Fcov150h.gif